

From: Lawrence Green
Sent: Thursday, May 16, 2019 1:32 PM
To: Eide, Tamara J.
Subject: CGRP

Hi Tamara,

This is Dr. Larry Green, I received word about Idaho's review of the CGRP products for migraine. Migraine is one of the main conditions I see most in my clinic. Since their release the treatment response has been excellent for migraine patients. Most patients seen here in the office are and have been the most resistant, I am using all of the formulations. Preferably I would like to see open access to all three products. It is not known yet if a patient may respond more to one over another, so some of us are just now considering switching therapies if no significant response to first choice. Response rates are unpredictable, but I do like the Ajovy product because of its 3 month data, making it preferable for busy /traveling working patients. If you or the committee have any questions, I would be happy to comply. Thanks you in advance. Lawrence Green, MD.